Cancer metastasis: Molecular mechanisms and clinical perspectives

Pharmacol Ther. 2023 Oct:250:108522. doi: 10.1016/j.pharmthera.2023.108522. Epub 2023 Sep 1.

Abstract

Metastatic progression combined with non-responsiveness towards systemic therapy often shapes the course of disease for cancer patients and commonly determines its lethal outcome. The complex molecular events that promote metastasis are a combination of both, the acquired pro-metastatic properties of cancer cells and a metastasis-permissive or -supportive tumor micro-environment (TME). Yet, dissemination is a challenging process for cancer cells that requires a series of events to enable cancer cell survival and growth. Metastatic cancer cells have to initially detach themselves from primary tumors, overcome the challenges of their intravasal journey and colonize distant sites that are suited for their metastases. The implicated obstacles including anoikis and immune surveillance, can be overcome by intricate intra- and extracellular signaling pathways, which we will summarize and discuss in this review. Further, emerging modulators of metastasis, like the immune-microenvironment, microbiome, sublethal cell death engagement, or the nervous system will be integrated into the existing working model of metastasis.

Keywords: Cancer; Epithelial-mesenchymal transition (EMT); Metastasis; Persister; Sublethal cell death engagement; Tumor (immune) micro-environment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anoikis
  • Epithelial-Mesenchymal Transition
  • Humans
  • Neoplasm Metastasis
  • Neoplasms* / metabolism
  • Signal Transduction
  • Tumor Microenvironment